Major Cost Drivers in Assessing the Economic Burden of Alzheimer’s Disease: A Structured, Rapid Review

@article{Klie2021MajorCD,
  title={Major Cost Drivers in Assessing the Economic Burden of Alzheimer’s Disease: A Structured, Rapid Review},
  author={Melodi Kosaner Klie{\ss} and R. Martins and Mark P. Connolly},
  journal={The Journal of Prevention of Alzheimer's Disease},
  year={2021},
  volume={8},
  pages={362-370}
}
Background Alzheimer’s Disease is the most common cause of dementia, affecting memory, thinking and behavior. Symptoms eventually grow severe enough to interfere with daily tasks. AD is predicted to increase healthcare spending and costs associated with formal and informal caregiving. The aim of this study was to identify and quantify the contribution of the different cost components associated with AD. Methods A structured literature review was conducted to identify studies reporting the… 
4 Citations

Figures and Tables from this paper

Evaluation of the Fiscal Costs and Consequences of Alzheimer’s Disease in Germany: Microsimulation of Patients’ and Caregivers’ Pathways
Alzheimer’s disease is a severe condition, impacting individual’s wellbeing and independence in daily activities. Informal care provision is common and of great value to societies but is not without
Modelling the value of innovative treatments for Alzheimer’s disease in the United States
TLDR
The importance and challenges of assimilating the perspectives of varied stakeholders, including patients, caregivers, health systems, payers, and society at large, into a comprehensive value assessment model that may be well suited for a breakthrough treatment for AD are examined.
Contribution of Iranian researchers in Alzheimer's disease research: A 10 years scientometric analysis
TLDR
It is found that Iranian researchers made significant impacts in the field of Alzheimer's disease and covered a wide range of related areas over the last 10 years.

References

SHOWING 1-10 OF 71 REFERENCES
Longitudinal costs of caring for people with Alzheimer's disease
TLDR
Higher levels of dependence in people with Alzheimer's disease are significantly associated with increased costs of informal care as the disease progresses, and formal care services did not respond to increased dependence, leaving it to families to fill the caring gap.
Cross sectional observational study on the societal costs of Alzheimer's disease.
TLDR
The societal costs of AD are very high, especially for patients with moderate and severe AD, which implies that treatments with the ability to delay progression of the disease into more severe stages have the potential to save large costs for society.
Cost and care of patients with Alzheimer's disease: clinical predictors in German health care settings.
The study aims to report service use and costs for patients with Alzheimer's disease (AD) and to explore the incremental influence of sociodemographic and illness-related determinants in ambulatory
Relationship between global severity of patients with Alzheimer’s disease and costs of care in Spain; results from the co-dependence study in Spain
TLDR
Dementia severity, measured by CDR score, showed that with increasing severity of the disease, direct medical, social care, informal care and total costs augmented, with informal care accounting for the greatest part.
Resource Use and Cost of Alzheimer's Disease in France: 18-Month Results from the GERAS Observational Study.
  • T. Rapp, S. Andrieu, B. Vellas
  • Medicine, Psychology
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
  • 2018
Costs and quality of life in community-dwelling patients with Alzheimer's disease in Spain: results from the GERAS II observational study
TLDR
Societal costs associated with AD in Spain were largely attributable to caregiver informal care costs and increased with increasing AD dementia severity.
Costs and Resource Use Associated with Community-Dwelling Patients with Alzheimer’s Disease in Japan: Baseline Results from the Prospective Observational GERAS-J Study
TLDR
Baseline results of GERAS-J showed that total monthly societal costs associated with AD dementia increased with AD severity, and caregiver-related costs were the largest cost component.
Association between illness progression measures and total cost in Alzheimer’s disease
TLDR
The repeated measures models confirmed a significant association between the DS and total care cost indicating an increase in cost with increasing dependence, and strategies which prevent deterioration in clinical measures or delay dependence should result in total cost savings.
Costs and Resource Use Associated with Alzheimer’s Disease in Italy: Results from an Observational Study
TLDR
Total Italian societal costs generally increased with increasing AD dementia severity, however, costs were slightly lower for moderate than for mild AD dementia, possibly reflecting the observed unusual trend of greater caregiver time and higher memantine use in patients with mild versus moderate AD dementia.
...
...